Cell Signaling Technology Logo - Extra Large
View Featured Offers >>
  1. Products /
  2. Primary Antibodies /
  3. FCN3 (F9E8J) Rabbit Monoclonal Antibody
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

FCN3 (F9E8J) Rabbit Monoclonal Antibody #63132

Filter:
  • WB

    Product Specifications

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 33
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    FCN3 (F9E8J) Rabbit Monoclonal Antibody recognizes endogenous levels of total FCN3 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala236 of human FCN3 protein.

    Background

    The complement system plays a critical role in the innate immune response to infection (1-3). Three distinct pathways, the classical, alternative, and lectin pathways, work to regulate complement (2). In humans, there are four recognition proteins in the lectin pathway: mannose-binding lectin (MBL) and 3 ficolin proteins, FCN1, FCN2, and FCN3 (1,2). Ficolin-3 (FCN3) was originally identified as the Hakata antigen, a macroglycoprotein that showed reactivity with serum from systemic lupus erythematosus (SLE) patients (1,5,6). FCN3 contains an N-terminal collagen-like domain that mediates oligomerization, and a C-terminal fibrinogen-like domain that binds to N-acetyl compounds found on the surfaces of microorganisms, resulting in complement activation (2). This activation generates complexes that disrupt and destroy abnormal cells. Complement fragments interact with immune cells, such as macrophages, neutrophils, and dendritic cells; these interactions enhance chemotaxis, phagocytic capacity, and antigen-presentation, boosting adaptive immunity (2,3). Accordingly, dysregulation in complement pathways has been shown to correlate with susceptibility to infection and autoimmunity (3-6). FCN3 is highly expressed in the lung and liver. Recent work has focused on the role of FCN3 in cancers (7-9). FCN3 is downregulated in lung and esophageal tumors (7,8). In analysis of FCN3 in serum from hepatocellular carcinoma (HCC) patients, low expression was associated with poor prognosis (9).

    Alternate Names

    Collagen/fibrinogen domain-containing lectin 3 p35; Collagen/fibrinogen domain-containing protein 3; FCN3; FCNH; ficolin (collagen/fibrinogen domain containing) 3 (Hakata antigen); ficolin 3; Ficolin-3; H-ficolin; HAKA1; Hakata antigen

    Database Links

    UniProt ID: O75636


    Entrez-Gene Id: 8547


    Limited Uses

    Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

    Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.